A Non-interventional Study With Advanced Lung Squamous Cell Carcinoma
NCT ID: NCT05984017
Last Updated: 2024-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
130 participants
OBSERVATIONAL
2021-07-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer
NCT03505515
Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China
NCT02458651
A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments
NCT06617390
A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery
NCT05872763
Survival Outcomes of Lung Cancer
NCT03647098
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No treatment is included in this study
No drug intervention or tissue sampling will be included in this study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Provision of fully informed consent prior to any study specific procedures.
* Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology.
* According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hunan Province Tumor Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yongchang Zhang
Professor, Deputy Director of Thoracic Oncology Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yongchang Zhang, MD
Role: PRINCIPAL_INVESTIGATOR
Hunan Cancer Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yongchang Zhang
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHR-1701 RWS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.